Reducing Selling, General and Administrative Expenses through Operational Efficiency Improvements and a Review of Staffing Levels
First written in FY2017. 6 of 9 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2025: 2 of 13 companies on the "Worse" side.
11 other companies' latest entry also says "Advanced".
- FY2024AdvancedAnnual report
「Operating profit was ¥2,110 million, compared with ¥1,410 million in the previous fiscal year, due to the aforementioned revenue growth and efforts to improve productivity through the digital transformation of operations, among other factors.」
The report specifically identifies productivity improvements through the digital transformation of operations as a factor behind KSK's operating profit exceeding the previous fiscal year's result. - FY2022RestatedAnnual report
「In addition, we focused on reducing costs by reviewing business processes.」
The company continues to pursue cost reductions through business process reviews as a measure in the pharmaceutical wholesale business. - FY2022-Q3RestatedAnnual report
「In addition, we focused on reducing costs by reviewing business processes.」
The company continues to pursue cost reductions through business process reviews as a measure in the pharmaceutical wholesale business. - FY2022-Q2RestatedAnnual report
「In addition, we focused on reducing costs by reviewing business processes.」
The company continues to pursue cost reductions through business process reviews as a measure in the pharmaceutical wholesale business. - FY2022-Q1RestatedAnnual report
「In addition, we focused on reducing costs by reviewing business processes.」
The company continues to pursue cost reductions through business process reviews as a measure in the pharmaceutical wholesale business. - FY2021AdvancedAnnual report
「Selling, general and administrative expenses were ¥40,478 million, down 2.9% year on year. This was mainly due to reviews of personnel expenses accompanying the deterioration in business performance and lower activity expenses, such as travel expenses, during the COVID-19 pandemic.」
The report states that SG&A declined by 2.9%, or ¥1,211 million, year on year through operational efficiency and workforce reviews. - FY2020RestatedAnnual report
「The dispensing pharmacy business advanced cost-reduction measures while responding to the April 2018 revisions to dispensing fees and drug prices.」
Cost-reduction measures addressing revisions to dispensing fees and drug prices are cited as a factor in the recovery of the dispensing pharmacy business. - FY2018RestatedAnnual report
「We also worked to reduce SG&A through operational efficiency and sought to secure profit.」
The company continues to reduce SG&A through operational efficiency as a measure to secure profit. - FY2017First statedAnnual report
「Selling, general and administrative expenses decreased by ¥624 million from the previous consolidated fiscal year as a result of efforts to reduce costs through operational efficiency, workforce reviews and other measures.」
The annual report identified, for the first time as a theme, the reduction of SG&A achieved through operational efficiency and workforce reviews.